Foghorn Therapeutics (FHTX) Stock Forecast, Price Target & Predictions
FHTX Stock Forecast
Foghorn Therapeutics stock forecast is as follows: an average price target of $18.00 (represents a 139.04% upside from FHTX’s last price of $7.53) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
FHTX Price Target
The average price target for Foghorn Therapeutics (FHTX) is $18.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $20.00 to $14.00. This represents a potential 139.04% upside from FHTX's last price of $7.53.
FHTX Analyst Ratings
According to 5 Wall Street analysts, Foghorn Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for FHTX stock is 0 'Strong Buy' (0.00%), 4 'Buy' (80.00%), 1 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Foghorn Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 19, 2024 | Gavin Clark-Gartner | Evercore ISI | $20.00 | $6.26 | 219.49% | 165.60% |
| Jan 05, 2023 | - | BMO Capital | $20.00 | $6.53 | 206.28% | 165.60% |
| Nov 21, 2022 | - | Morgan Stanley | $14.00 | $7.87 | 77.89% | 85.92% |
| Aug 23, 2022 | Vikram Purohit | Morgan Stanley | $15.00 | $10.89 | 37.74% | 99.20% |
The latest Foghorn Therapeutics stock forecast, released on Aug 19, 2024 by Gavin Clark-Gartner from Evercore ISI, set a price target of $20.00, which represents a 219.49% increase from the stock price at the time of the forecast ($6.26), and a 165.60% increase from FHTX last price ($7.53).
Foghorn Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 1 |
| Avg Price Target | $20.00 | $20.00 | $20.00 |
| Last Closing Price | $7.53 | $7.53 | $7.53 |
| Upside/Downside | 165.60% | 165.60% | 165.60% |
In the current month, the average price target of Foghorn Therapeutics stock is $20.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 165.60% increase as opposed to Foghorn Therapeutics's last price of $7.53. This month's average price target is down 0.00% compared to last quarter, and down 0.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 03, 2024 | Jefferies | - | Buy | Initialise |
| Aug 19, 2024 | Evercore ISI | - | Outperform | Initialise |
| Jun 29, 2023 | Goldman Sachs | Buy | Buy | Hold |
| Jan 05, 2023 | BMO Capital | - | Outperform | Initialise |
| Nov 21, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Aug 23, 2022 | Morgan Stanley | Overweight | Hold | Downgrade |
| May 23, 2022 | Morgan Stanley | Overweight | Overweight | Hold |
Foghorn Therapeutics's last stock rating was published by Jefferies on Sep 03, 2024. The company Initialise its FHTX rating from "null" to "Buy".
Foghorn Therapeutics Financial Forecast
Foghorn Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $17.48M | $5.60M | $5.31M | $4.18M | $6.63M | - | $3.92M | $713.00K | $41.00K | $279.00K | $286.00K | $251.00K | $179.00K |
| Avg Forecast | $15.00M | $15.00M | $12.00M | $12.00M | $7.07M | $6.34M | $6.04M | $6.91M | $4.54M | $4.58M | $6.32M | $5.04M | $8.48M | $9.19M | $9.58M | $9.43M | $709.75K | $30.75K | $279.00K | $190.67K | $500.00K | $626.33K |
| High Forecast | $15.00M | $15.00M | $12.00M | $12.00M | $7.07M | $7.06M | $6.04M | $6.91M | $6.94M | $4.58M | $6.32M | $5.04M | $8.48M | $9.19M | $9.58M | $11.05M | $831.74K | $36.03K | $326.95K | $223.44K | $585.94K | $733.98K |
| Low Forecast | $15.00M | $15.00M | $12.00M | $12.00M | $7.07M | $5.43M | $6.04M | $6.91M | $1.49M | $4.58M | $6.32M | $5.04M | $8.48M | $9.19M | $9.58M | $7.81M | $587.76K | $25.46K | $231.05K | $157.90K | $414.06K | $518.68K |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | - | 3.81% | 0.89% | 1.05% | 0.49% | 0.72% | - | 0.42% | 1.00% | 1.33% | 1.00% | 1.50% | 0.50% | 0.29% |
Foghorn Therapeutics's average Quarter revenue forecast for Dec 23 based on 4 analysts is $4.54M, with a low forecast of $1.49M, and a high forecast of $6.94M. FHTX's average Quarter revenue forecast represents a -74.01% decrease compared to the company's last Quarter revenue of $17.48M (Sep 23).
Foghorn Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-17.08M | $-31.17M | $-33.32M | $-37.14M | $-24.93M | - | $-26.10M | $70.59M | $-24.72M | $-21.83M | $-21.73M | $1.06M | $236.51K |
| Avg Forecast | $-9.00M | $-9.00M | $-7.20M | $-7.20M | $-4.24M | $-3.80M | $-3.62M | $-4.15M | $-2.73M | $-2.75M | $-3.79M | $-3.02M | $-5.09M | $-5.51M | $-5.75M | $-5.66M | $-425.85K | $-22.85M | $-21.83M | $-22.07M | $-300.00K | $-375.80K |
| High Forecast | $-9.00M | $-9.00M | $-7.20M | $-7.20M | $-4.24M | $-3.26M | $-3.62M | $-4.15M | $-893.76K | $-2.75M | $-3.79M | $-3.02M | $-5.09M | $-5.51M | $-5.75M | $-4.69M | $-352.66K | $-18.28M | $-17.47M | $-17.66M | $-248.44K | $-311.21K |
| Low Forecast | $-9.00M | $-9.00M | $-7.20M | $-7.20M | $-4.24M | $-4.24M | $-3.62M | $-4.15M | $-4.16M | $-2.75M | $-3.79M | $-3.02M | $-5.09M | $-5.51M | $-5.75M | $-6.63M | $-499.04K | $-27.42M | $-26.20M | $-26.49M | $-351.56K | $-440.39K |
| Surprise % | - | - | - | - | - | - | - | - | - | 6.21% | 8.22% | 11.02% | 7.30% | 4.52% | - | 4.61% | -165.77% | 1.08% | 1.00% | 0.98% | -3.52% | -0.63% |
1 analysts predict FHTX's average Quarter EBITDA for Mar 22 to be $-5.66M, with a high of $-4.69M and a low of $-6.63M. This is -108.01% lower than Foghorn Therapeutics's previous annual EBITDA (Dec 21) of $70.59M.
Foghorn Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | - | $-14.35M | $-29.49M | $-30.49M | $-34.13M | $-23.28M | - | $-26.02M | $170.75M | $-26.08M | $-23.11M | $-22.99M | $-68.80K | - |
| Avg Forecast | $-12.38M | $-13.41M | $-15.47M | $-14.96M | $-24.14M | $-22.18M | $-32.88M | $-32.67M | $-38.38M | $-36.11M | $-36.62M | $-36.49M | $-30.64M | $-29.53M | $-24.29M | $-22.20M | $-31.37M | $-24.10M | $-23.11M | $-23.35M | $-17.86M | $-128.82M |
| High Forecast | $-12.38M | $-13.41M | $-15.47M | $-14.96M | $-24.14M | $-18.93M | $-32.88M | $-32.67M | $-30.60M | $-36.11M | $-36.62M | $-36.49M | $-30.64M | $-29.53M | $-24.29M | $-17.24M | $-24.36M | $-19.28M | $-18.49M | $-18.68M | $-13.87M | $-100.04M |
| Low Forecast | $-12.38M | $-13.41M | $-15.47M | $-14.96M | $-24.14M | $-26.51M | $-32.88M | $-32.67M | $-45.66M | $-36.11M | $-36.62M | $-36.49M | $-30.64M | $-29.53M | $-24.29M | $-27.16M | $-38.38M | $-28.93M | $-27.73M | $-28.02M | $-21.86M | $-157.60M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.40% | 0.81% | 0.84% | 1.11% | 0.79% | - | 1.17% | -5.44% | 1.08% | 1.00% | 0.98% | 0.00% | - |
Foghorn Therapeutics's average Quarter net income forecast for Mar 22 is $-22.20M, with a range of $-27.16M to $-17.24M. FHTX's average Quarter net income forecast represents a -113.00% decrease compared to the company's last Quarter net income of $170.75M (Dec 21).
Foghorn Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | - | $8.31M | $8.40M | $8.64M | $7.86M | $7.96M | - | $7.22M | $-15.37M | $5.81M | $4.90M | $4.69M | $4.56M | $2.56M |
| Avg Forecast | $138.06M | $138.06M | $110.45M | $110.45M | $65.03M | $58.34M | $55.60M | $63.60M | $41.81M | $42.18M | $58.21M | $46.37M | $78.03M | $84.56M | $88.21M | $86.80M | $6.53M | $283.03K | $2.57M | $1.75M | $4.60M | $5.76M |
| High Forecast | $138.06M | $138.06M | $110.45M | $110.45M | $65.03M | $65.00M | $55.60M | $63.60M | $63.87M | $42.18M | $58.21M | $46.37M | $78.03M | $84.56M | $88.21M | $101.71M | $7.66M | $331.67K | $3.01M | $2.06M | $5.39M | $6.76M |
| Low Forecast | $138.06M | $138.06M | $110.45M | $110.45M | $65.03M | $49.94M | $55.60M | $63.60M | $13.71M | $42.18M | $58.21M | $46.37M | $78.03M | $84.56M | $88.21M | $71.88M | $5.41M | $234.38K | $2.13M | $1.45M | $3.81M | $4.77M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.20% | 0.14% | 0.19% | 0.10% | 0.09% | - | 0.08% | -2.35% | 20.52% | 1.91% | 2.67% | 0.99% | 0.44% |
Foghorn Therapeutics's average Quarter SG&A projection for Dec 23 is $41.81M, based on 4 Wall Street analysts, with a range of $13.71M to $63.87M. The forecast indicates a 403.28% rise compared to FHTX last annual SG&A of $8.31M (Sep 23).
Foghorn Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.34 | $-0.70 | $-0.73 | $-0.82 | $-0.56 | - | $-0.63 | $4.62 | $-0.71 | $-0.63 | $-0.62 | $-0.00 | $-0.51 |
| Avg Forecast | $-0.24 | $-0.26 | $-0.30 | $-0.29 | $-0.47 | $-0.43 | $-0.64 | $-0.63 | $-0.74 | $-0.70 | $-0.71 | $-0.71 | $-0.59 | $-0.57 | $-0.57 | $-0.53 | $-0.74 | $-0.68 | $-0.61 | $-0.60 | $-0.42 | $-3.05 |
| High Forecast | $-0.24 | $-0.26 | $-0.30 | $-0.29 | $-0.47 | $-0.37 | $-0.64 | $-0.63 | $-0.59 | $-0.70 | $-0.71 | $-0.71 | $-0.59 | $-0.57 | $-0.57 | $-0.41 | $-0.58 | $-0.52 | $-0.47 | $-0.47 | $-0.33 | $-2.37 |
| Low Forecast | $-0.24 | $-0.26 | $-0.30 | $-0.29 | $-0.47 | $-0.51 | $-0.64 | $-0.63 | $-0.89 | $-0.70 | $-0.71 | $-0.71 | $-0.59 | $-0.57 | $-0.57 | $-0.64 | $-0.91 | $-0.83 | $-0.75 | $-0.74 | $-0.52 | $-3.73 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.49% | 0.99% | 1.03% | 1.38% | 0.98% | - | 1.20% | -6.23% | 1.05% | 1.03% | 1.03% | 0.01% | 0.17% |
According to 1 Wall Street analysts, Foghorn Therapeutics's projected average Quarter EPS for Mar 22 is $-0.53, with a low estimate of $-0.64 and a high estimate of $-0.41. This represents a -111.36% decrease compared to FHTX previous annual EPS of $4.62 (Dec 21).
Foghorn Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PMVP | PMV Pharmaceuticals | $1.50 | $24.75 | 1550.00% | Buy |
| IPSC | Century Therapeutics | $1.46 | $20.00 | 1269.86% | Buy |
| MOLN | Molecular Partners | $5.51 | $29.00 | 426.32% | Buy |
| STTK | Shattuck Labs | $3.50 | $12.00 | 242.86% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.80 | $6.00 | 233.33% | Buy |
| RZLT | Rezolute | $4.35 | $12.50 | 187.36% | Buy |
| EWTX | Edgewise Therapeutics | $17.52 | $48.00 | 173.97% | Buy |
| MLYS | Mineralys Therapeutics | $11.23 | $30.00 | 167.14% | Buy |
| FHTX | Foghorn Therapeutics | $7.53 | $18.00 | 139.04% | Buy |
| STOK | Stoke Therapeutics | $14.70 | $33.33 | 126.73% | Buy |
| CCCC | C4 Therapeutics | $5.40 | $11.33 | 109.81% | Hold |
| PRLD | Prelude Therapeutics | $4.85 | $8.75 | 80.41% | Sell |
| CGEM | Cullinan Oncology | $17.98 | $32.00 | 77.98% | Buy |
| NRIX | Nurix Therapeutics | $23.33 | $27.57 | 18.17% | Buy |
| KYMR | Kymera Therapeutics | $45.40 | $51.10 | 12.56% | Buy |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |
FHTX Forecast FAQ
Is Foghorn Therapeutics a good buy?
Yes, according to 5 Wall Street analysts, Foghorn Therapeutics (FHTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 80.00% of FHTX's total ratings.
What is FHTX's price target?
Foghorn Therapeutics (FHTX) average price target is $18 with a range of $14 to $20, implying a 139.04% from its last price of $7.53. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Foghorn Therapeutics stock go up soon?
According to Wall Street analysts' prediction for FHTX stock, the company can go up by 139.04% (from the last price of $7.53 to the average price target of $18), up by 165.60% based on the highest stock price target, and up by 85.92% based on the lowest stock price target.
Can Foghorn Therapeutics stock reach $11?
FHTX's average twelve months analyst stock price target of $18 supports the claim that Foghorn Therapeutics can reach $11 in the near future.
What is Foghorn Therapeutics's current price target trend?
1 Wall Street analyst forecast a $20 price target for Foghorn Therapeutics (FHTX) this month, up 165.60% from its last price of $7.53. Compared to the last 3 and 12 months, the average price target increased by 165.60% and increased by 165.60%, respectively.
What are Foghorn Therapeutics's analysts' financial forecasts?
Foghorn Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $26.35M (high $27.08M, low $25.44M), average EBITDA is $-15.813M (high $-15.265M, low $-16.247M), average net income is $-112M (high $-109M, low $-116M), average SG&A $242.58M (high $249.23M, low $234.17M), and average EPS is $-2.169 (high $-2.106, low $-2.253). FHTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $54M (high $54M, low $54M), average EBITDA is $-32.4M (high $-32.4M, low $-32.4M), average net income is $-56.223M (high $-56.223M, low $-56.223M), average SG&A $497.03M (high $497.03M, low $497.03M), and average EPS is $-1.09 (high $-1.09, low $-1.09).
Did the FHTX's actual financial results beat the analysts' financial forecasts?
Based on Foghorn Therapeutics's last annual report (Dec 2023), the company's revenue was $34.16M, beating the average analysts forecast of $20.49M by 66.71%. Apple's EBITDA was $-108M, beating the average prediction of $-12.293M by 777.81%. The company's net income was $-98.426M, missing the average estimation of $-148M by -33.31%. Apple's SG&A was $32.37M, missing the average forecast of $188.57M by -82.83%. Lastly, the company's EPS was $-0.0023, missing the average prediction of $-2.861 by -99.92%. In terms of the last quarterly report (Sep 2023), Foghorn Therapeutics's revenue was $17.48M, beating the average analysts' forecast of $4.58M by 281.38%. The company's EBITDA was $-17.081M, beating the average prediction of $-2.75M by 521.20%. Foghorn Therapeutics's net income was $-14.345M, missing the average estimation of $-36.106M by -60.27%. The company's SG&A was $8.31M, missing the average forecast of $42.18M by -80.30%. Lastly, the company's EPS was $-0.34, missing the average prediction of $-0.7 by -51.43%